Beta Drugs Quarterly Results for Trading Insights
Latest Quarter Net Profit
₹12 Cr
QSept 2025
In Sept 2025, Beta Drugs (BETA) reported revenue ₹106 Cr and net profit ₹12 Cr. Compare with BETA DCF valuation to assess whether the stock is under or overvalued.
BETA Quarterly Results — Revenue, Profit & EPS Highlights
Beta Drugs latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit Beta Drugs screener.
- Revenue of ₹106 Cr in Sept 2025 (+8.2% vs Mar 2025)
- Net Profit of ₹12 Cr in Sept 2025 (+33.3% vs Mar 2025)
- EBITDA of ₹24 Cr in Sept 2025 (+26.3% vs Mar 2025)
- Operating Margin of 21.0% in Sept 2025 (+5.0pp vs Mar 2025)
- Earnings Per Share of ₹12.10 in Sept 2025 (+35.2% vs Mar 2025)
Beta Drugs Quarterly Results — Revenue, EBITDA, Net Profit & EPS
BETA quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | Dec 2024 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 106 | 98 | 103 | 90 | 89 | 8.2% | - |
| Net Profit (₹ Cr) | 12 | 9 | 12 | 9 | 9 | - | - |
| EBITDA (₹ Cr) | 24 | 19 | 23 | 19 | 17 | - | - |
| EPS (₹) | 12.10 | 8.95 | 11.59 | 8.40 | 9.31 | - | - |
| Operating Margin (%) | 21.0% | 16.0% | 20.0% | 19.0% | 18.0% | - | - |
BETA Share Price Trend — 1-Year Movement Across Quarterly Results
Beta Drugs 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Also explore BETA share price data to track price trends across different timeframes.
Revenue Trend (₹ Cr)
Dec 2025
90
Jun 2025
103
Mar 2025
98
Sept 2025
106
Net Profit Trend (₹ Cr)
Dec 2025
9
Jun 2025
12
Mar 2025
9
Sept 2025
12
Operating Margin Trend (%)
Dec 2025
19.0%
Jun 2025
20.0%
Mar 2025
16.0%
Sept 2025
21.0%
BETA vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Beta Drugs latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Sept 2025 |
₹443,373.10 Cr | 1824.8 | 14,875 | 3,125 | +10.8% | - | 21.0% | 140.4 |
|
Divis Laboratories
Sept 2025 |
₹178,235.60 Cr | 6796.0 | 2,860 | 689 | +7.1% | - | 24.1% | 261.7 |
|
Torrent Pharmaceuti…
Sept 2025 |
₹145,389.39 Cr | 4295.8 | 3,219 | 591 | +11.3% | - | 18.4% | 244.9 |
|
Cipla
Mar 2026 |
₹107,240.96 Cr | 1327.6 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 193.2 |
|
Dr Reddys Laborator…
Mar 2026 |
₹105,607.38 Cr | 1265.3 | 7,996 | 221 | -12.5% | -11.5% | 2.8% | 477.5 |
Sector Quarterly Performance Comparison
Healthcare sector • Latest quarterly results
▲ Positive Growth
▼ Negative Growth
- No Data
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores
All amounts in ₹ Crores